Oculis (OCS) 2026 Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
2026 Global Healthcare Conference summary
15 Sep, 2026Pipeline overview and clinical progress
Two advanced programs in phase III: Licaminlimab for TNFR1 dry eye and Privosegtor for acute optic neuritis.
Licaminlimab uses a precision medicine approach, genotyping patients for targeted treatment, with phase III readout expected late 2026 or early 2027.
Privosegtor, a neuroprotective agent, has shown strong phase II results and is in phase III with FDA breakthrough and EMA prime designations.
Both programs are in registration trials, with Privosegtor also being explored for MS relapses and NAION.
The company is well-financed through the second half of 2029, supporting ongoing and planned trials.
Licaminlimab: Dry eye disease program
Licaminlimab targets severe TNFR1-positive dry eye patients, using a qPCR saliva test for genotype selection.
Phase II data showed a sevenfold improvement in symptoms for TNFR1 patients; phase III focuses on symptom improvement in this group.
The drug is a topical antibody fragment administered as an eye drop three times daily.
Market potential includes 1.8 million TNFR1-positive patients in the U.S., with pricing expected to exceed current branded therapies.
Additional indications include uveitis, with plans for further development as a steroid-sparing agent.
Privosegtor: Acute optic neuritis and neuroprotection
Privosegtor was acquired to avoid royalties and milestones, and has advanced from phase I to phase III in three years.
Demonstrated significant functional and structural benefits in phase II, including improved LCVA and reduced retinal atrophy.
No current therapies alter prognosis in acute optic neuritis; Privosegtor addresses a major unmet need.
PIONEER-1 phase III trial is activating sites globally, aiming for 50% site activation by December to align with disease seasonality.
Commercial opportunity estimated at $3.5 billion in the U.S. alone, with pricing in line with orphan indications.
Latest events from Oculis
- Privosegtor advances neuroprotection while licaminlimab tests biomarker-guided dry-eye care.OCS
Stifel 2026 Healthcare Conference 2026 - PREDICT-1 readout nears as privosegtor advances across neuroprotection indications.OCS
3rd Annual Guggenheim Healthcare Innovation Conference - Late-stage trials advance as $252.0M in cash supports runway into 2H 2029.OCS
Q3 2026 - ACUITY signals support a registrational optic neuritis program for privosegtor.OCS
Euretina Innovation Spotlight (EIS) 2026 Presentation - TNFR1-guided dry-eye development targets greater benefit in biomarker-positive patients.OCS
Study presentation - Precision medicine and targeted trials drive clinical and commercial strategy, with strong funding.OCS
H.C. Wainwright 28th Annual Global Investment Conference - Privosegtor and Licaminlimab trials advance, with strong cash reserves supporting long-term growth.OCS
Q2 2026 - Late-stage neuro-ophthalmic and ophthalmic programs advance toward pivotal milestones with strong financial backing.OCS
Corporate presentation - Positive clinical results and precision medicine advances set the stage for major milestones in 2024–2025.OCS
H.C. Wainwright 26th Annual Global Investment Conference